Could gilteritinib keep AML in remission longer after transplant?

NCT ID NCT06734585

Completed Knowledge-focused Sponsor: Astellas Pharma Singapore Pte. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study looked at people with a type of leukemia (AML) that has a FLT3 gene change, which makes the cancer grow faster. After a stem cell transplant, some patients took the drug gilteritinib in earlier trials, while others received standard care. Researchers compared medical records to see if gilteritinib helped keep patients cancer-free longer. The study only collected existing data and did not provide any new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Gilteritinib (XOSPATA)
What this could lead to: If successful, this could confirm that gilteritinib helps keep FLT3-mutated AML patients cancer-free longer after a stem cell transplant, supporting its approval in more countries.
What could go wrong: This is an observational study using data from past trials and medical records, not a new treatment test. Results may not apply to all patients, and the comparison groups may differ in ways that affect outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

AU61001

Melbourne, Australia
AU61002

Melbourne, Australia
BR55001

São Paulo, Brazil
BR55002

Porto Alegre, Brazil
BR55003

São Paulo, Brazil
BR55004

Fortaleza, Brazil
CN86001

Tianjin, China
CN86003

Shanghai, China
CN86004

Suzhou, China
HK852001

Hong Kong, Hong Kong
KR82001

Seoul, South Korea
KR82002

Seoul, South Korea
KR82003

Seoul, South Korea
KR82004

Busan, South Korea
KR82005

Gwangju, South Korea
TW88601

Taipei, Taiwan
TW88602

Tainan, Taiwan
TW88603

Taichung, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.